HSE Drugs Group defers decision on drug to treat Friedrich’s ataxia to allow for further research

Craig Coady with a photograph of himself and his son Rory celebrating a sporting success. Craig says Rory’s memory gives him the strength to continue fighting for access to treatment for his surviving son, Paudie. Picture: Chani Anderson

The HSE Drugs Group has deferred a decision on the life-changing Skyclarys drug to treat Friedrich’s ataxia so that further research can be conducted.

The group met on Tuesday to discuss the drug, and a decision was made to defer the conversation about whether or not the drug will be approved for reimbursement for between three and four weeks.